title: [Rolipram, a specific type IV phosphodiesterase inhibitor, ameliorates indomethacin-induced gastric mucosal injury in rats].
abstract: Inhibition of type IV phosphodiesterase activity is beneficial in various inflammation mediated by its function to suppress the production of inflammatory cytokines in inflammatory cells. Nonsteroidal anti-inflammatory drugs(NSAIDs) such as indomethacin are well known to develop gastric mucosal lesion. As pathogenesis of indomethacin induced gastric mucosal lesion, activation of neutrophils and inflammatory cytokine production play critical roles. However, the effect of phosphodiesterase inhibitors on development of gastric mucosal lesion has not been reported. In the present study, we examined the effect of specific type IV phosphodiesterase inhibitor(rolipram) on NSAIDs-induced gastric mucosal lesion. Also, we examined the effect of rolipram on tissue prostaglandin E2 production.
authors.affiliation: First Department of Medicine, Akita University School of Medicine.
authors.forename: Chieko
authors.initials: C
authors.lastname: Nakamura
authors.forename: Michiro
authors.initials: M
authors.lastname: Otaka
authors.forename: Masaru
authors.initials: M
authors.lastname: Odashima
authors.forename: Sumio
authors.initials: S
authors.lastname: Watanabe
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D005753:Gastric Mucosa / Q000187:drug effects*; D007213:Indomethacin / Q000009:adverse effects*; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D051381:Rats; D020889:Rolipram / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010726:Phosphodiesterase Inhibitors; D020889:Rolipram; D007213:Indomethacin